Article
Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations.
Neoplasia (New York, N.Y.) - 1 Jul 2024
Xiong Kai, Yang Yi, Yang Yanan, Wang Zhengbo, Liu Yun, Duo Hong, Yuan Xinya, Xiao Yao, Xiao He, Yang Xueqin
Abstract excerpt
BACKGROUND: Tyrosine kinase inhibitors (TKIs) are standard first-line treatments for advanced non-small-cell lung cancer (NSCLC) with driver gene mutations. The Response Evaluation Criteria in Solid Tumors (RECIST) are limited in predicting long-term patient benefits. A tumour marker-based evaluation criteria, RecistTM, was used to investigate the potential for assessing targeted-therapy efficacy in lung cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.